Key Developments: Guided Therapeutics Inc (GTHP.OB)


3:59pm EDT
Change (% chg)

$0.00 (+2.19%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Guided Therapeutics, Inc reaffirms FY 2015 revenue outlook
Wednesday, 13 May 2015 04:05pm EDT 

Guided Therapeutics, Inc:Continue to project sales of $3 million for FY 2015.  Full Article

Guided Therapeutics, Inc completes interim financing
Wednesday, 15 Apr 2015 08:05am EDT 

Guided Therapeutics, Inc:Completes sale of 4 mln shares of common stock to purchase an additional 2mln shares, for an aggregate purchase price of $720,000 in private placement to accredited investors.  Full Article

Guided Therapeutics announces pricing of $3.8 mln public offering
Wednesday, 26 Nov 2014 10:20am EST 

Guided Therapeutics Inc:Announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of about 16.8 million shares of its common stock, and warrants to purchase shares of its common stock.For gross proceeds to the company of about $3.8 million.Expects to use the cash proceeds to continue to seek FDA approval for LuViva, to repay certain bridge loans, and to support general working capital and operations.  Full Article

Guided Therapeutics, Inc announces secured note offering - Form 8-K
Wednesday, 10 Sep 2014 04:20pm EDT 

Guided Therapeutics, Inc:Enters into note purchase agreement with Tonaquint, Inc., pursuant to which the company sold a secured promissory note to Tonaquint with an initial principal amount of $1,275,000, for a purchase price of $700,000.Note does not bear interest, and will be due six months from issuance.  Full Article

Guided Therapeutics, Inc. initiates Cervical Cancer Screening Trial for LuViva Advanced Cervical Scan
Tuesday, 19 Aug 2014 08:01am EDT 

Guided Therapeutics, Inc:Begins enrollment this week in a multi-center clinical trial to expand claims for the LuViva(reg) Advanced Cervical Scan to include front-line screening for cervical cancer.The trial will be run by principal investigator, Dr. Daron G. Ferris, Director, HPV Prevention Program and Professor of Obstetrics and Gynecology at the Medical College of Georgia at Georgia Regents University in Augusta, Georgia.The blinded trial is expected to enroll between 600 and 800 women, 160 women in Augusta and the remainder in Peru.The results will be used to update and validate LuViva's software for use as a primary screener for cervical disease that leads to cancer, much like the Pap test is used today.LuViva will be compared with Visual Examination with Acetic Acid, or VIA, with cytology, HPV, colposcopy and biopsy, where taken, as the Gold Standard. The trial is expected to take six to nine months.  Full Article

Guided Therapeutics announces completion of private placement of senior convertible notes
Friday, 23 May 2014 04:05pm EDT 

Guided Therapeutics Inc:Announced that it has issued and sold to Magna Group affiliate Hanover Holdings I, LLC the final $2,000,000 in principal amount of senior convertible notes.Intends to use the proceeds for general corporate purposes, including to support manufacturing and marketing of the Guided Therapeutics LuViva Advanced Cervical Scan.  Full Article

Guided Therapeutics Inc announces private placement of senior convertible notes
Thursday, 24 Apr 2014 08:00am EDT 

Guided Therapeutics Inc:Agreed to sell in private placement to Hanover Holdings I, LLC, an affiliate of Magna Group up to $3,000,000 in aggregate principal amount of 6 pct Senior Convertible Notes due 18 months from the date of issuance.Net proceeds are intended to be used for general corporate purposes, including to support manufacturing and marketing of Guided Therapeutics LuViva Advanced Cervical Scan.Etico Capital acted as sole placement agent for private placement.  Full Article

Guided Therapeutics Inc names gene cartwright as Chief Executive Officer
Tuesday, 7 Jan 2014 08:05am EST 

Guided Therapeutics Inc:Says Gene Cartwright has been appointed as the Chief Executive Officer effective Jan. 6.Says Cartwright replaces Mark L. Faupel, who has transitioned to the role of Chief Scientific Officer.  Full Article

Guided Therapeutics Inc Receives $250,000 Payment For Licensing Property
Wednesday, 23 Oct 2013 08:32am EDT 

Guided Therapeutics Inc announced that it received a $250,000 payment from Freedom Meditech, Inc., a San Diego, California based ophthalmic medical device company. The payment was received as part of an agreement under which Guided Therapeutics licensed certain of its non-core intellectual property to Freedom Meditech for technology development related to scanning optical properties of the lens of the eye. Under the agreement, Guided Therapeutics is paid on milestones, minimum royalties and royalties on sales of Freedom Meditech`s products that use Guided Therapeutics` intellectual property, up to a cap of $4 million. To date, payments received by Guided Therapeutics under the license agreement total $300,000.  Full Article

No consensus analysis data available.
Search Stocks